Medical devices industry M&A deals in September 2019 total $1.26bn globally

26 October 2019 (Last Updated October 26th, 2019 08:53)

Medical devices industry M&A deals in September 2019 total $1.26bn globally

Total medical devices industry M&A deals in September 2019 worth $1.26bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 31.8% over the previous month and a drop of 66.2% when compared with the last 12-month average, which stood at $3.72bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $768.94m. At the country level, the US topped the list in terms of deal value at $768.94m.

In terms of volumes, North America emerged as the top region for medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of M&A deals activity in September 2019 was the US with 17 deals, followed by France with four and Germany with three.

In 2019, as of the end of September 2019, medical devices M&A deals worth $31.59bn were announced globally, marking an increase of 39.8% year on year.

Medical devices industry M&A deals in September 2019: Top deals

The top five medical devices industry M&A deals accounted for 98% of the overall value during September 2019.

The combined value of the top five medical devices M&A deals stood at $1.23bn, against the overall value of $1.26bn recorded for the month.

The top five medical devices industry deals of September 2019 tracked by GlobalData were:

1) Stryker’s $500m acquisition of GYS Tech and Mobius Imaging

2) The $450m acquisition of EndoSpan by CryoLife

3) Baxter International’s $230m acquisition of Cheetah Medical

4) The $27.85m acquisition of RAL Diagnostics by CellaVision

5) OncoCyte’s acquisition of Razor Genomics for $25m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.